Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G2/mitotic-specific cyclin-B1 (CCNB1) is a key regulatory protein essential for the control of the cell cycle at the G2/M transition. It complexes with cyclin-dependent kinase 1 (CDK1) to form the maturation-promoting factor (MPF), which drives the cell from the G2 phase into mitosis. CCNB1 expression is tightly regulated, peaking during the G2/M phase and rapidly degrading as cells exit mitosis. In many cancers, including breast, lung, and colorectal cancers, CCNB1 is constitutively overexpressed, promoting uncontrolled cell proliferation and tumor progression. Consequently, CCNB1 is a highly attractive therapeutic target in oncology. Therapeutic strategies include small-molecule inhibitors of the CDK1/CCNB1 complex (such as CID-078, dinaciclib, and RO-3306), natural products that downregulate its expression (such as resveratrol), and peptide-based cancer vaccines designed to elicit an immune response against CCNB1-overexpressing tumor cells.
Inhibition of the CDK1/Cyclin B1 complex, downregulation of CCNB1 expression, or active immunotherapy targeting CCNB1-expressing tumor cells
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G2/mitotic-specific cyclin-B1 (CCNB1).